Esiflo 100 Transcaps is a combination medication containing Salmeterol 50 mcg and Fluticasone Propionate 100 mcg, indicated for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). Salmeterol is a long-acting beta2-adrenergic receptor agonist that provides bronchodilation by relaxing airway smooth muscle, thereby improving airflow and reducing symptoms such as wheezing and shortness of breath. Fluticasone Propionate is a potent inhaled corticosteroid with anti-inflammatory properties that decrease airway inflammation, reduce mucus production, and prevent exacerbations. The synergistic effect of these agents helps achieve better asthma control and reduces the frequency of exacerbations compared to monotherapy. Esiflo 100 Transcaps is administered via inhalation, allowing direct delivery to the lungs and minimizing systemic exposure. It is intended for regular use and not for relief of acute bronchospasm. Common side effects may include throat irritation, hoarseness, and oral candidiasis; therefore, patients are advised to rinse their mouth after inhalation. Use of Esiflo 100 Transcaps should be under medical supervision, with dosage adjustments based on clinical response and severity of the disease. It is contraindicated in patients with hypersensitivity to its components and should be used cautiously in individuals with cardiovascular disorders.